CD34 and myeloproliferative disorder: At the moment of leukemic conversion, the DNA samples used for NGS testing were extracted from two cell fractions isolated from BMMC— CD34+ cells to include a part of the blast cell population and CD3+ T cells to serve as non-tumoral tissue control— as previously suggested for molecular analysis in MPN patients (18).